Published Tuesday, June 15 2010
Mississauga, Ontario June 15, 2010 – Theramed Corporation announces an extension until March 31, 2018 of their exclusive right to import, market and distribute COLLATAMP® G in Canada. This was an extension of the original agreement assigned to Theramed in 2008 with EUSA Pharma Ltd. COLLATAMP®...
Published Friday, June 19 2009
Use this page to stay up-to-date on the latest developments in preventing hospital-acquired infections, including methicillin-resistant staphylococcus aureus (MRSA), C. difficile and surgical site infections. MRSA Superbug Study Tracks Infection Patients, staff and visitors all help spread drug-resistant...
Published Wednesday, April 15 2009
TORONTO – 35 Leading Canadian hospitals in Ontario and Quebec have now begun using a dramatically new and effective approach to prevent and treat deadly and costly surgical site infections (SSIs). Collatamp G is an implantable form of antibiotic that is left-behind in the surgical wound prior to...
Published Sunday, March 15 2009
TORONTO – As Ontario hospitals prepare to begin mandatory public reporting of surgical site infection (SSI) rates this month, Mississauga-based Theramed Corporation has launched a new website ( www.collatampg.ca ) to help patients better understand the risks of SSIs and prevention strategies. Surgical...
Published Monday, March 02 2009
TORONTO – Mississauga-based Theramed Corporation has released an economic model demonstrating significant hospital cost benefits of using Collatamp G as a powerful adjunct to current standards of care in preventing costly and deadly surgical site infections (SSIs). Surgical site infections are...
Published Sunday, February 15 2009
TORONTO – Effective April 30, 2009, the Ontario Ministry of Health and Long Term Care is instituting mandatory public reporting of surgical site infection (SSI) rates at all Ontario hospitals. Currently, MRSA and C. difficile rates are also publicly reported. Surgical site infections are devastating...
Published Thursday, January 15 2009
TORONTO – Surgical site infections (SSIs) are devastating to patient safety and hospital budgets. SSIs double patients’ risk of dying and cost the Canadian healthcare system over $200 million, and 400,000 bed days annually. Now, a new antibiotic "sponge" is available in Canada which...
Published Monday, November 17 2008
Gentamicin Surgical Implant, presently sold in Canada under the brand name Collatamp G, is currently being evaluated in the US in two phase III clinical trials as an adjunct to systemic antibiotic administration for the prevention of surgical site infections in patients who are at higher risk of developing...
Published Tuesday, September 02 2008
TORONTO —Mississauga-based Theramed Corporation is pleased to announce their newly-formed partnership with the Canadian Society of Colon and Rectal Surgeons (CSCRS). Theramed, Canadian distributors of Collatamp G, an antibiotic implant for the prevention of surgical infections, has committed to...
Published Wednesday, May 14 2008
Bourne Capital Partners, LLC ("Bourne Partners") through its Canadian subsidiary, Critique Pharmaceuticals Inc., announces the acquisition of the Theramed Corporation ("Theramed"). Theramed is a full-service Canadian medical device, pharmaceutical and biotech commercialization company...
